In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
The company has an advanced management team, Efficient manufacturing team, experienced domestic and foreign sales team, professional technical research and development team
This broad-spectrum effectiveness makes it a powerful therapeutic agent for patients suffering from chronic gastric ulcers
Still, could she be overlooking something
On top of that, there's just so many of them, and they're evolving so quickly that having reference standards and being able to detect them is really, really challenging